Using its chemoinformatics technologies, MolGenie has designed and synthesized novel, small molecule compounds as putative GPCR antagonists. With financial support […]
Using its chemoinformatics technologies, MolGenie has designed and synthesized novel, small molecule compounds as putative GPCR antagonists. With financial support […]